Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

被引：1
|
作者：
McNamara, Blair [1 ]
Bellone, Stefania [1 ]
Demirkiran, Cem [1 ]
Hartwich, Tobias Max Philipp [1 ]
Santin, Alessandro D. [1 ,2 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
[2] 333 Cedar St,LSOG 305,POB 208063, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2023年 / 48卷
关键词：
Lenvatinib; Pembrolizumab; Clear Cell Ovarian cancer; Recurrent; Treatment-resistant;
D O I：
10.1016/j.gore.2023.101218
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Background: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. Case: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the com-bination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles. Conclusion: The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
    Yamashita, Shimpei
    Kawabata, Hiroki
    Iwahashi, Yuya
    Muraoka, Satoshi
    Wakamiya, Takahito
    Kojima, Fumiyoshi
    Kohjimoto, Yasuo
    Murata, Shin-ichi
    Hara, Isao
    IJU CASE REPORTS, 2025,
  • [32] The proteome of clear cell ovarian carcinoma
    Ji, Jennifer X.
    Cochrane, Dawn R.
    Negri, Gian Luca
    Colborne, Shane
    Miko, Sandra E. Spencer
    Hoang, Lynn N.
    Farnell, David
    Tessier-Cloutier, Basile
    Huvila, Jutta
    Thompson, Emily
    Leung, Samuel
    Chiu, Derek
    Chow, Christine
    Ta, Monica
    Kobel, Martin
    Feil, Lucas
    Anglesio, Michael
    Goode, Ellen L.
    Bolton, Kelly
    Morin, Gregg B.
    Huntsman, David G.
    JOURNAL OF PATHOLOGY, 2022, 258 (04): : 325 - 338
  • [33] cell death chemotherapy induced by Nelfinavir - resistant ovarian carcinoma cells
    Lenhard, M.
    Bruening, A.
    Vogel, M.
    Burger, P.
    Rahmeh, M.
    Gingelmaier, A.
    Friese, K.
    Burges, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (08) : 751 - 751
  • [34] PHASE II TRIAL OF PEMBROLIZUMAB AND EPACADOSTAT IN RECURRENT CLEAR CELL CARCINOMA OF THE OVARY: AN NRG ONCOLOGY STUDY
    Gien, Lilian
    Enserro, Danielle
    Block, Matthew
    Waggoner, Steven
    Duska, Linda
    Hendrickson, Andrea Wahner
    Thaker, Premal
    Backes, Floor
    Bottsford-Miller, Justin
    Muller, Carolyn
    Disilvestro, Paul
    Covens, Allan
    Gershenson, David
    Moore, Kathleen
    Aghajanian, Carol
    Coleman, Robert L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A9 - A9
  • [35] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [36] Morphologic Changes in Ovarian Carcinoma After Neoadjuvant Chemotherapy: Report of a Case Showing Extensive Clear Cell Changes Mimicking Clear Cell Carcinoma
    Chew, Ivy
    Soslow, Robert A.
    Park, Kay J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (05) : 442 - 446
  • [37] Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma
    Al-Barrak, J.
    Santos, J. L.
    Tinker, A.
    Hoskins, P.
    Gilks, C. B.
    Lau, H.
    Swenerton, K. D.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 107 - 110
  • [38] Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Gallego, A.
    Ramon-Patino, J.
    Brenes, J.
    Mendiola, M.
    Berjon, A.
    Casado, G.
    Castelo, B.
    Espinosa, E.
    Hernandez, A.
    Hardisson, D.
    Feliu, J.
    Redondo, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (03): : 536 - 542
  • [39] Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    A. Gallego
    J. Ramon-Patino
    J. Brenes
    M. Mendiola
    A. Berjon
    G. Casado
    B. Castelo
    E. Espinosa
    A. Hernandez
    D. Hardisson
    J. Feliu
    A. Redondo
    Clinical and Translational Oncology, 2021, 23 : 536 - 542
  • [40] The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer
    Barbi, Mali
    Lee, Chung-Shien
    Rahman, Husneara
    Cheng, Kit
    Jean, Lee
    John, Veena S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345